Investigating biomarkers and regulatory mechanisms associated with depression and anxiety in obesity based on transcriptome sequencing and experimental validation

For many people, the struggle with weight is not just about calories or exercise; it is often a battle fought on two fronts at once. A growing body of medical knowledge has shown that carrying excess weight and suffering from mental health challenges like depression or anxiety are deeply intertwined. They do not simply happen to the same person by chance; rather, they seem to fuel one another in a complex biological loop. When the body is in a state of obesity, it often triggers low-level inflammation and metabolic shifts that can reach into the brain, altering mood and behavior. Conversely, the stress and chemical changes of depression can drive behaviors that lead to weight gain. Despite knowing these connections exist, doctors and scientists have lacked a clear map of the specific molecular signals that link the two conditions. Without knowing exactly which genes or proteins are misfiring, it is difficult to create targeted treatments that address both the physical and mental aspects of the problem simultaneously.

A team of researchers from the First Teaching Hospital of Tianjin University of Traditional Chinese Medicine has taken a significant step toward filling this gap. By treating the body's genetic instructions as a vast library of data, they searched for the specific genetic switches that go wrong when obesity and mental distress occur together. Their work did not rely on guessing or observing symptoms alone; instead, they used powerful computer algorithms to sift through thousands of genetic profiles from public medical databases. They looked for patterns that appeared in people with obesity and compared them against patterns found in people with depression and anxiety. The goal was to find the common genetic thread that ties these conditions together, hoping to identify reliable biological markers that could signal the presence of these comorbidities before they become severe.

The researchers began by gathering genetic data from blood samples of people with obesity and comparing them to healthy controls. They then did the same for data from people suffering from both depression and anxiety. By finding the genes that were altered in both groups, they narrowed down a massive list of possibilities to just a handful of candidates. Using advanced machine learning techniques, which act like a highly trained filter to spot the most important signals in a sea of noise, they identified two specific genes that stood out. These genes, named CPOX and SLC35F5, were consistently found to be working at lower levels in people with obesity compared to those without. The researchers confirmed this finding by testing the genes in a new set of data and then by analyzing actual blood samples from patients in their own hospital, where the results held true.

To understand what these two genes might be doing, the team looked at where they are active in the body and what biological pathways they influence. They found that CPOX is highly active in organs like the liver and bone marrow, while SLC35F5 is more common in the thyroid and kidneys. Inside the cells, CPOX lives in the fluid-filled center, whereas SLC35F5 is found in the nucleus, the command center of the cell. The study suggests that when these genes are turned down, it disrupts the body's ability to manage energy and process certain chemicals. Specifically, the research points to a breakdown in how the body handles inflammation and how it communicates with the immune system. The immune system, which usually protects the body from invaders, appears to become overactive in a way that damages tissue and confuses the brain's chemical signals, potentially leading to the feelings of anxiety and depression seen in obese patients.

The researchers did not stop at identifying the genes; they also tried to see if these findings could help sort patients into different groups who might need different treatments. By analyzing the genetic profiles of the obese patients, they discovered that the group was not uniform. Instead, the patients fell into two distinct molecular subtypes, which the researchers called C1 and C2. These subtypes had different genetic signatures and different patterns of immune cell activity. This distinction is crucial because it suggests that a "one-size-fits-all" approach to treating obesity and its mental health side effects might not work. Some patients might have a specific type of inflammation driven by one set of genes, while others have a different mechanism entirely.

With these subtypes defined, the team turned to the question of treatment. They used computer simulations to test how various existing drugs might interact with the specific genes found in each subtype. They were looking for molecules that could bind tightly to the proteins produced by the CPOX gene, effectively turning the gene back on or stabilizing its function. For the first subtype, C1, the simulation identified a drug called mazindol as having a very strong connection to the target. For the second subtype, C2, a different drug called FK-866 showed the strongest binding. While these drugs were not tested in patients within this study, the computer models suggest that they could theoretically correct the specific genetic errors found in each group. This approach of matching a drug to a specific genetic profile represents a move toward precision medicine, where treatment is tailored to the individual's unique biology rather than a general diagnosis.

The study concludes that the genes CPOX and SLC35F5 are not just passive markers but likely play an active role in the complex relationship between obesity, depression, and anxiety. Their reduced activity seems to be a key part of the mechanism that links metabolic health with mental well-being. The researchers built a predictive model based on these two genes that could accurately distinguish between obese and non-obese individuals, suggesting that measuring these genes could one day help doctors identify patients at risk for mental health complications. However, the authors are careful to note that their findings are based on computer analysis and initial lab tests. The next step would be to confirm these results in larger groups of people and to see if treating these specific genetic pathways actually improves both weight and mood in clinical trials. For now, the work provides a new, concrete target for understanding how the body and mind are connected, offering a potential roadmap for future therapies that treat the whole person.